Invicta completes 47% stake sale in Porteus Medical
Invicta Diagnostic Limited completed the sale of its 47% stake in Porteus Medical LLP on May 16, 2026, for a consideration of ₹47000. The subsidiary had a nil turnover in FY 2024-25 and a net worth of Rs. 1.25 Lakhs. The transaction does not require compliance with regulation 37A of the LODR Regulations.
*this image is generated using AI for illustrative purposes only.
Invicta Diagnostic Limited has completed the sale of its 47% stake in Porteus Medical LLP. The company executed the third supplementary LLP agreement on May 16, 2026, finalizing the transaction that was initially intimated to the exchanges on January 05, 2026.
The sale consideration amounted to ₹47000. The buyers included Dr. Vishwajeet Arvind Burungale, Dr. Aniruddha Joshi, Dr. Girish Govindrao Kakde, and Dr. Shriganesh Patil, all of whom are radiologists. The company confirmed that none of the buyers belong to the promoter group or group companies.
Financial Details of Subsidiary
According to the disclosures, Porteus Medical LLP reported a turnover of Rs. NIL for the financial year 2024-25. The net worth of the entity as on March 31, 2025, stood at Rs. 1.25 Lakhs, which represented 0.07% of the consolidated net worth of Invicta Diagnostic Limited.
| Particulars | Details |
|---|---|
| Stake Sold | 47% |
| Consideration Received | ₹47000 |
| Date of Agreement | May 16, 2026 |
| Date of Completion | May 16, 2026 |
| Turnover FY 2024-25 | Rs. NIL |
| Net Worth (March 31, 2025) | Rs. 1.25 Lakhs |
Transaction Compliance
The company stated that the transaction does not fall within related party transactions and was not conducted at arm's length. As the sale constitutes 0.07% of the consolidated net worth of the company, which is less than 20%, the compliance requirements under regulation 37A of the LODR Regulations are not applicable. The disclosures regarding the sale have been uploaded to the company's website.
Historical Stock Returns for Invicta Diagnostic
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -4.98% | -25.31% | -17.32% | -30.87% | -30.87% | -30.87% |
How will Invicta Diagnostic Limited redeploy the proceeds from the Porteus Medical LLP stake sale to drive future growth or acquisitions?
What does the exit from a zero-turnover entity like Porteus Medical LLP signal about Invicta Diagnostic's broader strategy for rationalizing non-performing subsidiaries or partnerships?
Could the acquisition of the 47% stake by a group of radiologists indicate a potential expansion or revival of Porteus Medical LLP's diagnostic operations under new leadership?
15
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
